Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 44Gastrointestinal 11Tumor-Agnostic 6CNS 6Dermatologic 5Thoracic 4Sarcoma 4Gynecologic 4Head & Neck 3Endocrine 3Other solid neoplasm 2Other hematologic neoplasm 1NET 1Breast 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Axitinib × Endocrine × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Columbia University

Phase 2 Active not recruiting
6 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT01435122 2018-10-02

A Study of Axitinib in Advanced Carcinoid Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
30 enrolled 10 charts
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡